본문 바로가기
KERD
논문KCI 등재

Comparison of Comorbidities in Relation to Critical Conditions among Coronavirus Disease 2019 Patients: A Network Meta-Analysis

Hoang Tung|Tran Thi Anh Tho
대한감염학회 (The Korean Society Of Infectious Diseases)|2021.03|Infection and Chemotherapy|제53권 제1호|pp. 13-28|DOI 10.3947/ic.2020.0136

2

조회

0

다운로드

9

인용

0

참고문헌

키워드

COVID-19SeverityComorbidityIntensive care unitAcute respiratory distress syndrome
주제분류내과학

초록

Severe illness and poor outcome are mainly associated with aging or certain medical comorbidities, especially chronic diseases. However, factors for unfavorable prognosis have not been well described owing to relatively small sample sizes and single-center reports. Therefore, this study aimed to compare the contribution of comorbidities in the development of critical conditions in coronavirus disease 2019 (COVID-19) patients. Pooled estimates of relative risks (RRs) and their 95% confidence intervals (CIs) were calculated by conducting a meta-analysis and network meta-analysis of 18 studies. Chronic obstructive pulmonary disease (COPD) was most strongly associated with the overall critical condition (RR = 4.22, 95% CI = 3.12 - 5.69), followed by cardiovascular disease (CVD) (RR = 3.00, 95% CI = 2.41 - 3.73), malignancy (RR = 2.91, 95% CI = 2.16 - 3.91), cerebrovascular accident (CVA) (RR = 2.86, 95% CI = 1.95 - 4.19), diabetes (RR = 2.10, 95% CI = 2.16 - 3.91), hypertension (RR = 2.02, 95% CI = 1.82 - 2.23), and chronic kidney disease (RR = 2.00, 95% CI = 1.36 - 2.94). The presence of comorbidities except for chronic liver disease and chronic kidney disease significantly increased the risk of severe infection, intensive care unit (ICU) admission, and cardiac injury in the subgroup analysis by types of critical conditions. Preexisting hypertension and diabetes additionally increased the risk of acute respiratory distress syndrome (ARDS). Among comorbidities, COPD had the highest probability of leading to severe COVID-19, ICU admission, and liver injury, while malignancy was most likely to cause ARDS and cardiac injury. In summary, preexisting COPD, CVD, CVA, hypertension, diabetes, and malignancy are more likely to worsen the progression of COVID-19, with severe infection, ICU admission requirement, and cardiac injury development.

Abstract

Severe illness and poor outcome are mainly associated with aging or certain medical comorbidities, especially chronic diseases. However, factors for unfavorable prognosis have not been well described owing to relatively small sample sizes and single-center reports. Therefore, this study aimed to compare the contribution of comorbidities in the development of critical conditions in coronavirus disease 2019 (COVID-19) patients. Pooled estimates of relative risks (RRs) and their 95% confidence intervals (CIs) were calculated by conducting a meta-analysis and network meta-analysis of 18 studies. Chronic obstructive pulmonary disease (COPD) was most strongly associated with the overall critical condition (RR = 4.22, 95% CI = 3.12 - 5.69), followed by cardiovascular disease (CVD) (RR = 3.00, 95% CI = 2.41 - 3.73), malignancy (RR = 2.91, 95% CI = 2.16 - 3.91), cerebrovascular accident (CVA) (RR = 2.86, 95% CI = 1.95 - 4.19), diabetes (RR = 2.10, 95% CI = 2.16 - 3.91), hypertension (RR = 2.02, 95% CI = 1.82 - 2.23), and chronic kidney disease (RR = 2.00, 95% CI = 1.36 - 2.94). The presence of comorbidities except for chronic liver disease and chronic kidney disease significantly increased the risk of severe infection, intensive care unit (ICU) admission, and cardiac injury in the subgroup analysis by types of critical conditions. Preexisting hypertension and diabetes additionally increased the risk of acute respiratory distress syndrome (ARDS). Among comorbidities, COPD had the highest probability of leading to severe COVID-19, ICU admission, and liver injury, while malignancy was most likely to cause ARDS and cardiac injury. In summary, preexisting COPD, CVD, CVA, hypertension, diabetes, and malignancy are more likely to worsen the progression of COVID-19, with severe infection, ICU admission requirement, and cardiac injury development.

참고문헌 (65)

  1. Xia S, "Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion", Cell Res, 30, pp.343~355 (2020)
  2. Wang C, "A novel coronavirus outbreak of global health concern", Lancet, 395, pp.470~473 (2020)
  3. Bedford J, "COVID-19: towards controlling of a pandemic", Lancet, 395, pp.1015~1018 (2020)
  4. Xiao Y, "Taking the right measures to control COVID-19", Lancet Infect Dis, 20, pp.523~524 (2020)
  5. "Latest News: Coronavirus USA live updates: news summary for July 4th"[URL]
  6. Wu Z, "Characteristics of and Important Lessons From the Coronavirus Disease 2019(COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention", JAMA, 323, pp.1239~1242 (2020)
  7. Novel coronavirus (2019-nCoV) situation, "WHO", ~, pp.report-92 (2020)
  8. Grasselli G, "Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy:Early Experience and Forecast During an Emergency Response", JAMA, 323, pp.1545~1546 (2020)
  9. White DB, "A Framework for Rationing Ventilators and Critical Care Beds During the COVID-19Pandemic", JAMA, 323, pp.1773~1774 (2020)
  10. Hoang Tung, "Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence", Infection and Chemotherapy, 52(3), pp.317~334 (2020), 대한감염학회[DOI]
  11. Kim Sun Bean, "Interim Guidelines on Antiviral Therapy for COVID-19", Infection and Chemotherapy, 52(2), pp.281~304 (2020), 대한감염학회[DOI]
  12. 신형식, "Empirical Treatment and Prevention of COVID-19", Infection and Chemotherapy, 52(2), pp.142~153 (2020), 대한감염학회[DOI]
  13. 강승지, "Age-Related Morbidity and Mortality among Patients with COVID-19", Infection and Chemotherapy, 52(2), pp.154~164 (2020), 대한감염학회[DOI]
  14. Yang X, "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study", Lancet Respir Med, 8, pp.475~481 (2020)
  15. Liu K, "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province", Chin Med J, 133, pp.1025~1031 (2020)
  16. Higgins JP, "Measuring inconsistency in meta-analyses", BMJ, 327, pp.557~560 (2003)
  17. Sterne JA, "Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis", J Clin Epidemiol, 54, pp.1046~1055 (2001)
  18. Egger M, "Bias in meta-analysis detected by a simple, graphical test", BMJ, 315, pp.629~634 (1997)
  19. Skonieczna-Żydecka K, "A systematic review, meta-analysis, and meta-regression evaluating the efficacy and mechanisms of action of probiotics and synbiotics in the rrevention of surgical site infections and surgery-related complications", J Clin Med, 7, pp.556~ (2018)
  20. Hoang T, "Comparative efficacy of targeted therapies in patients with non-small cell lung cancer: a network meta-analysis of clinical trials", J Clin Med, 9, pp.1063~ (2020)
  21. Wan S, "Clinical features and treatment of COVID-19 patients in northeast Chongqing", J Med Virol, 92, pp.797~806 (2020)
  22. Qin C, "Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China", Clin Infect Dis, 71, pp.762~768 (2020)
  23. Liu W, "Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease", Chin Med J (Engl), 133, pp.1032~1038 (2020)
  24. Li YK, "Clinical and transmission characteristics of Covid-19 - a retrospective study of 25 cases from a single thoracic surgery department", Curr Med Sci, 40, pp.295~300 (2020)
  25. Li X, "Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan", J Allergy Clin Immunol, 146, pp.110~118 (2020)
  26. Lei Z, "A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China", Travel Med Infect Dis, 35, pp.101664~ (2020)
  27. Guan WJ, "Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis", Eur Respir J, 55, pp.2000547~ (2020)
  28. Wu C, "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019pneumonia in Wuhan, China", JAMA Intern Med, 180, pp.934~943 (2020)
  29. Liu Y, "Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury", Sci China Life Sci, 63, pp.364~374 (2020)
  30. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
  31. Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
  32. Chen T, "Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study", BMJ, 368, pp.m1091~ (2020)
  33. Xie H, "Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study", Liver Int, 40, pp.1321~1326 (2020)
  34. Zhang JJ, "Clinical characteristics of 140patients infected with SARS-CoV-2 in Wuhan, China", Allergy, 75, pp.1730~1741 (2020)
  35. Wang Z, "Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China", Clin Infect Dis, 71, pp.769~777 (2020)
  36. Wang L, "Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China", Am J Nephrol, 51, pp.343~348 (2020)
  37. Wang D, "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China", JAMA, 323, pp.1061~1069 (2020)
  38. Shi S, "Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China", JAMA Cardiol, 5, pp.802~810 (2020)
  39. Liu H, "Comorbid chronic diseases are strongly correlated with disease severity among COVID-19 patients: a systematic review and meta-analysis", Aging Dis, 11, pp.668~678 (2020)
  40. Jain V, "Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis", Int J Public Health, 65, pp.533~546 (2020)
  41. Wrapp D, "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation", Science, 367, pp.1260~1263 (2020)
  42. Restrepo MI, "COPD is associated with increased mortality in patients with community-acquired pneumonia", Eur Respir J, 28, pp.346~351 (2006)
  43. Chen Y, "In a retrospective study of chronic obstructive pulmonary disease inpatients, respiratory comorbidities were significantly associated with prognosis", J Clin Epidemiol, 58, pp.1199~1205 (2005)
  44. Rello J, "Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia", Eur Respir J, 27, pp.1210~1216 (2006)
  45. Bansal M, "Cardiovascular disease and COVID-19", Diabetes Metab Syndr, 14, pp.247~250 (2020)
  46. Ferrario CM, "ffect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensinconverting enzyme 2", Circulation, 111, pp.2605~2610 (2005)
  47. Li XC, "The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases", Pharmacol Res, 125, pp.21~38 (2017)
  48. Giudicessi JR, "Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)", Mayo Clin Proc, 95, pp.1213~1221 (2020)
  49. Clini EM, "Chronic obstructive pulmonary disease is just one component of the complex multimorbidities in patients with COPD", Am J Respir Crit Care Med, 187, pp.668~671 (2013)
  50. Vanfleteren LE, "Does COPD stand for “COmorbidity with Pulmonary Disease”?", Eur Respir J, 45, pp.14~17 (2015)
  51. Hong KW, "Clinical courses and outcomes of hospitalized adult patients with seasonal influenza in Korea, 2011-2012: Hospital-based Influenza Morbidity & Mortality (HIMM) surveillance", J Infect Chemother, 20, pp.9~14 (2014)
  52. Yang JK, "Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS", Diabet Med, 23, pp.623~628 (2006)
  53. Kulcsar KA, "Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection", JCI Insight, 4, pp.e131774~ (2019)
  54. Geerlings SE, "Immune dysfunction in patients with diabetes mellitus (DM)", FEMS Immunol Med Microbiol, 26, pp.259~265 (1999)
  55. Moutschen MP, "Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections", Diabete Metab, 18, pp.187~201 (1992)
  56. King GL, "The role of inflammatory cytokines in diabetes and its complications", J Periodontol, 79(8Suppl), pp.1527~1534 (2008)
  57. Lippi G, "Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis", Pol Arch Intern Med, 130, pp.304~309 (2020)
  58. Brown JD, "Antihypertensive drugs and risk of COVID-19?", Lancet Respir Med, 8, pp.e28~ (2020)
  59. Oyelade T, "Prognosis of COVID-19 in patients with liver and kidney diseases: an early systematic review and meta-analysis", Trop Med Infect Dis, 5, pp.80~ (2020)
  60. Syed-Ahmed M, "Immune dysfunction and risk of infection in chronic kidney disease", Adv Chronic Kidney Dis, 26, pp.8~15 (2019)
  61. Danser AHJ, "Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers", Hypertension, 75, pp.1382~1385 (2020)
  62. Liang W, "Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China", Lancet Oncol, 21, pp.335~337 (2020)
  63. Miyashita H, "Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City", Ann Oncol, 31 (2020)
  64. Dai M, "Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 Outbreak", Cancer Discov, 10, pp.783~791 (2020)
  65. Lee LY, "COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study", Lancet, 395, pp.1919~1926 (2020)

관련 논문AI추천

Predictors of Mortality in Patients with COVID-19: A Systematic Review and Meta-analysis김우림, 이경은, 한지민한국임상약학회 · 한국임상약학회지2020 · 제30권 제3호The anatomy of COVID-19 comorbidity networks among hospitalized Korean patients신은경, 최효영, Hayes Neil한국역학회 · Epidemiology and Health2021 · 제43권 Should all patients with hypertension be worried about developing severe coronavirus disease 2019 (COVID-19)?Alvanegh Akbar Ghorbani, Ataee Mohammad Reza, Bagheri Mehdi, Bahardoust Mansour, Goharrizi Mohammad Ali Sheikh Beig, Heiat Mohammad, Navidiyan Ensiyeh Shabani, Zijoud Seyed Reza Hosseini대한고혈압학회 · Clinical Hypertension2021 · 제27권 제2호New Scoring System for Predicting Mortality in Patients with COVID-19권기태, 김신우, 김윤정, 배소현, 장현하, 황소윤연세대학교의과대학 · Yonsei Medical Journal2021 · 제62권 제9호The Potential Role of Dyslipidemia in COVID-19 Severity: an Umbrella Review of Systematic Reviews강현, 김현민, 최근주한국지질동맥경화학회 · 지질·동맥경화학회지2020 · 제9권 제3호Is Obesity a Potential Risk factor for Poor Prognosis of COVID-19?COVID-19 Team, Dilek Ernam, Elif Yıldırım, Eylem Tuncay, Ipek Ozmen, Meltem Agca, Nazlı Huma Teke, Nermin Ozer Yılmaz, Reyhan Yıldız, Simge Yavuz, Tülin Sevim, Zuhal Karakurt대한감염학회 · Infection and Chemotherapy2021 · 제53권 제2호

이 간행물의 다른 논문 (17건)

Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief ReviewNasir Hassan, Kumari Priyanka, Lathiya Maulik, Michel George, Pandya Naushira, Halpern John, Sanchez-Gonzalez Marcos A., Offor Rita, Nwankwo Kanayo, Arif Uroosa, Waheed Khurram, Bhatt Kinal, Garimella Radhika, Taugir Rahima, Mehta Isha, Jamal Muhammad, Vijayan Rupalakshmipp. 1-12An Overview of Human Immunodeficiency Virus-1 Antiretroviral Drugs: General Principles and Current StatusYoon Cheol-Hee, Shin Young Hyun, Park Chul Minpp. 29-45Etiology, Characteristics, and Outcomes of Community-Onset Pyomyositis in Korea: A Multicenter StudyHong Hyo-Lim, 최성호, 최상호, 정지원, 조오현, Kim Min-Chul, Kwak Yee Gyung, Park Se Yoon, 김탁, Park Seong Yeon, Yu Shi Nae, Kim Yong Kyun, Song Eun Hee, Park Ki-Ho, The Korean SSTI Study Grouppp. 46-52Machine-Learning-Based Approach to Differential Diagnosis in Tuberculous and Viral MeningitisJeon Min Huok, Park Ki-Ho, 정영섭, Kim Min-Chul, Kim Sung-Han, 최승임, Park Joung Ha, Lee Yu-Mi, Lee Eunyoung, Choo Eun Ju, Kim Tae Hyong, Jeon Minjun, Kim Tark, Park Se Yoon, Lee Mi Suk, Park Seong Yeonpp. 53-62The Impact of Modifying Empirical Antibiotic Therapy Based on Intestinal Colonization Status on Clinical Outcomes of Febrile Neutropenic PatientsAlrstom Ali, Alsuliman Tamim, Daher Nizar, Abouharb Raedpp. 63-74
원문 보기